Understanding how TDP-43 protein affects brain cells in neurodegenerative diseases
Deciphering TDP-43 Proteinopathy: Unveiling the Consequences on Oligodendrocyte Dysfunction
This study is looking at how clumps of a protein called TDP-43 affect a special type of brain cell, which could help us understand diseases like ALS and Alzheimer's better and find new ways to treat them.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10883862 on NIH RePORTER |
What this research studies
This research investigates the role of TDP-43 protein aggregates in causing dysfunction in oligodendrocytes, a type of brain cell, which is linked to various neurodegenerative diseases such as ALS and Alzheimer's. The researchers will create laboratory models to explore how these protein aggregates spread and impact brain function. By examining the effects of TDP-43 on brain cells, the study aims to uncover the underlying mechanisms of these diseases and identify potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with neurodegenerative diseases such as ALS, Alzheimer's, or related conditions.
Not a fit: Patients with neurodegenerative diseases not associated with TDP-43 pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of neurodegenerative diseases.
How similar studies have performed: Previous research has shown that targeting protein aggregates in neurodegenerative diseases can lead to significant advancements, suggesting this approach may also yield valuable insights.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Porta Antolinez, Silvia — University of Pennsylvania
- Study coordinator: Porta Antolinez, Silvia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.